Navigation Links
Cara Therapeutics Secures $12.3 Million in Series C Extension Financing
Date:7/24/2008

SHELTON, Conn., July 24 /PRNewswire/ -- Cara Therapeutics, Inc. announced today that it had closed on $12.3 million of additional funding to its original $24 million Series C financing which was completed in 2007. The round was led by new investor, Devon Park Bioventures, and included participation by Connecticut Innovations. Previous investors participating in the round included; Ascent Biomedical Ventures, Mitsubishi International Corporation and Wistar Morris. In conjunction with the financing, Dr. Christopher Moller, General Partner at Devon Park Bioventures, will join Cara's Board of Directors. The additional funds will be used primarily for further clinical development of both intravenous and oral formulations of Cara's second generation peripherally-selective kappa opioid agonist, CR845.

About CR845

In preclinical studies, CR845 was highly selective for the peripheral kappa opioid receptor. Animal studies indicate that CR845 is effective in reducing pain of inflammatory, neuropathic and visceral origin. The analgesic and anti-inflammatory effects of CR845 lasted for up to 18 hours after a single dose. CR845 was active after intravenous, subcutaneous, or oral administration. Preclinical studies also indicate that CR845 possesses anti-itch properties. Unlike currently marketed opioids, CR845 did not inhibit intestinal transit (ileus), impair breathing or elicit signs of addiction in animal models. CR845 is currently completing Phase Ia studies.

About Cara Therapeutics

Cara Therapeutics is a privately held biotechnology company focused on developing novel, superior therapeutics to treat pain and inflammation associated with diverse medical conditions. Cara's current pipeline includes near-term clinical drug candidates within multiple classes of peripherally-acting analgesics. Cara also plans to develop entirely novel classes of analgesics that emerge from its proprietary GPCR DimerScreenTM technology.

Forward-Looking Sta
'/>"/>

SOURCE Cara Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)... NEW DELHI, India, Dec. 3 /PRNewswire-Asia/ -- Dr...at Shenzhen Beike Biotechnology Co. Ltd.,( http://...High-Risk Diabetic,Foot Care in New Delhi, India, ...ell research and regenerative medicine company. ,...odiatry Association (IPA), aimed,to help podiatris...
(Date:12/2/2009)... YORK, Dec. 2 Reportlinker.com ann...ble in its catalogue: ,, Carbondioxide Incubat...ww.reportlinker.com/p0164368/Carbondioxide-Incubat...ubators are the most critical equipment used in mi...applications for providing a controlled environmen...
(Date:12/2/2009)... Calif., Dec. 2 Peregrin...orted completion of patient enrollment in a dose c... patients with relapsed glioblastoma multiforme (G...s a targeted monoclonal antibody linked to a radio...nt for GBM. Cotara specifically targets cells at ...
(Date:12/2/2009)...RIDGE, Mass., Dec. 2 TechConnect W...chnology development and product integration in cl... December 11th deadline for technology abstracts a...ear, TechConnect World, in association with the Na...e Clean Technology and Sustainable Industries Orga...
Breaking Biology Technology:Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 2Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3
...Meeting of Shareholders to Vote on Proposed Merger...ember 20, 2007 -- -- McNeil Trust to Vo... Arrow International,Inc. (Nasdaq: ARRO ) today ...d Exchange Commission and mailed to Arrow sharehol... the Company,s 2007 Annual Meeting of,Shareholders...
... Md., Aug. 24 Stem cell company,Neuralstem, Inc. ...s shares,have been accepted for listing on the Ame... CUR. Neuralstem shares are expected to begin trad...ex is the next logical step for Neuralstem. It is ...s the company has made in,each and every phase of ...
... Aug. 23 eBioscience Corporation announced,the ap...science, effective,immediately. Dr. Nelson comes t... was Vice President, Global Corporate Development....Lai, eBioscience,s,founder, will remain as Preside...in eBioscience,s Board of Directors. Dr. Nelson c...
Other Biology Technology:Arrow International Files and Mails Definitive Proxy Materials 2Arrow International Files and Mails Definitive Proxy Materials 3Arrow International Files and Mails Definitive Proxy Materials 4Neuralstem Shares Accepted for Trading on Amex(R) 2Todd R. Nelson Named Chief Executive Officer of eBioscience, Inc. 2
(Date:12/3/2009)...nction of plant and animal species can be likened ... a cabinet full of potential medicines into the tr...d,s burgers. , But the decline of species and th...ew research now suggests it may also put you at gr...abitat destruction and biodiversity loss,"driven b...
(Date:12/3/2009)...ERQUE, N.M. Most scientists believe that staph in...ignal each other to emit toxins. The signaling pro...a must be present to start the process. , But th...the very first stage of staph infection, when bact...curs in a single cell and that this individual pro...
(Date:12/3/2009)...wellers must be included in the design of the upco... humanitarian crisis, according to a scientist at ...ture , Dr Simon Lewis argues that at least 50% of ...gen, known as REDD (Reducing Emissions from Defore... dwellers directly, and their property rights assu...
Breaking Biology News(10 mins):Species down, disease up 2Species down, disease up 3Species down, disease up 4Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 2Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 3Forest deal at Copenhagen must avoid creating 'carbon refugees' 2Kidney Community Launches Health Care Campaign to Improve Survival Rates of First Year Dialysis Patients in Iowa 48347 1Kidney Community Launches Health Care Campaign to Improve Survival Rates of First Year Dialysis Patients in Iowa 48347 2Kidney Community Launches Health Care Campaign to Improve Survival Rates of First Year Dialysis Patients in Iowa 48347 3Study finds colorectal cancer rates increasing worldwide 8769 1Study finds colorectal cancer rates increasing worldwide 8769 2Pharmacy Organizations Brief Congress on Medication Therapy Management 48343 1Pharmacy Organizations Brief Congress on Medication Therapy Management 48343 2Pharmacy Organizations Brief Congress on Medication Therapy Management 48343 3
...udy has shown promising results in fighting a seve...ghout the body. , Advances in genetic knowledge h...cent years. We now know which genes are linked to ...y few cures and treatments have developed as a res...searchers at Cardiff University suggests that a ch...
...phia, PA, 10 January 2008 A Web site is a better ...me or printed pamphlet, according to a study of lo...the Journal of Nutrition Education and Behavior ( ....D., of Michigan State University, East Lansing, t...th nutrition information in different formats. On...
...2008Zigzagging some 60,000 kilometers across ocean... pivotal role in many workings of the planet, from...e interior, and the chemistry of rock, water and a...s discovered the existence of vast plumbing system...rheat it, then spit it back out from seafloor vent...
Other Biology News:Genetic breakthrough offers promise in tackling kidney tumors 2For nutrition info, moms like the Web best 2Quakes under Pacific floor reveal unexpected circulatory system 2Quakes under Pacific floor reveal unexpected circulatory system 3
...77 amino acid polypeptide sequence corresponding t... by activation of a recombinant soluble proform of...C ACTIVITY:The specific activity of MT1-MMP cataly...ty that hydrolyzes 1 mol peptide (7-methoxycoumari...
..., lightweight, high current power supply capable o...is an excellent choice for PAGE, SDS-PAGE and DNA ...pes of electroblotting applications.A dual functio...run and wil automatically accrue elapsed time when...
Anti-Interferon-beta (IFNb) Monoclonal Antibody, Unconjugated from CHEMICON
...apor Trap Models RVT100, RVT400, RVT405DDA, RVT410... UVS400A and UVS800DDA., A non-corrosive, odorles...or use for temperatures ranging from -105 to +260 ...ability and does not evaporate. Far superior to dr...
Biology Products: